A biotechnology startup is poised to go public with a roughly $10 billion price tag a year before it begins human clinical trials for its drug candidates. That isn’t as crazy as it sounds. Sana Biotechnology, which is developing cell-engineering platforms that it says could change the way many diseases are treated, plans to sell […]